Biotech2k
Biotech Investor, AI-Driven Drug Discovery
IREN's long-term appeal rests on its standing as one of the best vertically integrated AI neoclouds. In the short term, the stock has not been this oversold since 2022. x.com
IREN's $8 billion in cash against a valuation of just $10 billion points to unfathomable upside potential. Its shares are back below their $28 IPO price. x.com
IREN's predatory management and markedly weaker execution than Nebius make it hard to take seriously while Mike Alfred remains on its board. Barring an oversold bounce, IREN looks cooked big time with more time. x.com x.com
Open-source models likely wrecked the heavy-capex thesis behind IREN. Debt CDS and falling token prices make the still-bullish view definitely less so. Unlike Roku, a previous long-term hold with a unique, massive user base, low capex and positive free cash flow, IREN lacks a clear path forward; without one, it is better not to hold it. If Warsh remains hawkish, a full exit from IREN is very likely. x.com x.com
IREN is worth $68 versus about $40 now, making this dip a generational buying opportunity for investors under 55. Microsoft gave IREN a $9.7B AI cloud contract, and its power is already secured. Real wealth is built by buying weeks like this and holding, not by buying all-time highs. x.com
IREN's worsening fundamentals warrant patience despite its potential. Trailing free cash flow is -$2.45 billion, net income -$703 million and EPS -$1.64 even as revenue has grown; it needs a catalyst change and a positive trend in fundamentals. x.com
IREN's $363 million in GPU-backed financing makes it a bet to survive neocloud consolidation. Elon Musk warned that drying debt markets could kill or consolidate many of the 200-plus neoclouds, leaving only a few survivors; IREN secured funding in that very market. x.com
IREN and Nebius look most attractive in AI cloud on projected 2027 revenue growth relative to their EV/revenue multiples. IREN is listed at 297% growth and 4.74x, and Nebius at 266% and 4.26x; TeraWulf and Cipher Mining have similar projected growth but multiples above 9x. x.com
IREN is an extreme diluter of shareholders, so peers offer better equity exposure to the data center buildout. Its share count rose from 50M in 2022 to 350M through ATMs, repeated convertibles and 40M shares sold at $42; a new $6B ATM could dilute 35% or more, and it issued 30M warrant shares to help pay for Nvidia GPUs. Its new $3B convertible runs seven years with a $110 cap; if the stock doesn't get there, Cipher, Nebius, Riot or Marathon look better. Bondholders may fare better. x.com x.com
IREN's forecast revenue ramp underpins the $100-plus share-price view. It will do $4 billion in ARR by Q1 and $13 billion by the end of next year; comparing today's share price and shares outstanding with its IPO overlooks that expected growth. x.com x.com